Sutimlimab (BIVV009) for the Adult Participants With Cold Agglutinin Disease (CAD) Who Have Completed Phase 3 Studies (CARDINAL or CADENZA) in Japan

Clinical trial NCT05132127 · COMPLETED

Trial details

NCT number: NCT05132127
Sponsor: Sanofi
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Cold Agglutinin Disease

Start date: 2021-11-11
Primary completion: 2022-11-15
Enrollment: 7

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.